Premium
A synergistic combination of Huperzine A, Convolvulus pluricaulis and Celastrus paniculatus promote cognitive function and health
Author(s) -
Ahmad Imtiaz,
Swaroop Anand,
Bagchi Debasis
Publication year - 2018
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.2018.32.1_supplement.656.7
Subject(s) - huperzine a , acetylcholinesterase , aché , donepezil , neuroprotection , pharmacology , cholinergic , medicine , acetylcholine , traditional medicine , chemistry , dementia , disease , biochemistry , enzyme
Approximately 56 billion dollars are spent as a result of traumatic brain injury and about 90,000 Americans suffer from long‐term disability. Uprising stress, busy lifestyle and unhealthy food habits are the major causes of traumatic brain injury. The majority of the treatment strategies are based on the improvement of cholinergic function in the brain and one of the emerging therapeutic target is to enhance the acetylcholine level in the brain. Standardized herbal extracts including Huperzia serrata, Convolvulus pluricaulis (Shankhapushpi; SP) and Celastrus paniculatus (Jyotismati; JY) are long been known to attenuate brain function and well‐being. Research studies have demonstrated the versatile roles of these novel phytochemicals as natural acetylcholinesterase inhibitors and neuroprotectants, and exhibited their efficacy in the management of neurological or memory impairment, dementia, Parkinson's and Alzheimer's disease. In the recent past, we developed a novel, standardized Huperzia serrata extract, CogniUp™ enriched with 1% Huperzine A, which demonstrated broad spectrum safety and neuroprotective abilities. In this study, we developed a unique combination of CogniUp, SP and JY (MZ001), which can effectively and synergistically inhibit acetylcholinesterase (AChE) inhibition. Based on our initial assessment, concentration‐dependent AChE inhibition kinetics was assessed individually using 0, 3.0, 6.0, 9.0, 12.0 and 24.0 mg SP/ml, while AChE inhibition kinetics was assessed individually using 0, 0.5, 1.0, 2.0, 4.0 and 8.0 mg JY/ml. Simultaneously, concentration‐dependent AChE inhibition kinetics was assessed individually using 0, 0.0625, 0.125, 0.25 and 0.5 μg CogniUp/ml. Several combinations were assessed and ultimately, we found that a combination of SP, JY and CogniUp (12 mg/ml, 4 mg/ml and 0.125 μg/ml) provided the most efficacious and synergistic AChE inhibition. No significant adverse events were observed. Further studies are in progress to establish the therapeutic efficacy of our unique proprietary combination‐MZ001 containing SP, JY and CogniUp. Support or Funding Information This project was funded by Cepham Inc., Piscataway, NJ This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .